TissGeneSummary for HGFAC |
Gene summary |
Basic gene information | Gene symbol | HGFAC |
Gene name | HGF activator | |
Synonyms | HGFA | |
Cytomap | UCSC genome browser: 4p16 | |
Type of gene | protein-coding | |
RefGenes | NM_001297439.1, NM_001528.3, | |
Description | hepatocyte growth factor activator | |
Modification date | 20141207 | |
dbXrefs | MIM : 604552 | |
HGNC : HGNC | ||
Ensembl : ENSG00000109758 | ||
HPRD : 05184 | ||
Vega : OTTHUMG00000090281 | ||
Protein | UniProt: go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_HGFAC | |
BioGPS: 3083 | ||
Pathway | NCI Pathway Interaction Database: HGFAC | |
KEGG: HGFAC | ||
REACTOME: HGFAC | ||
Pathway Commons: HGFAC | ||
Context | iHOP: HGFAC | |
ligand binding site mutation search in PubMed: HGFAC | ||
UCL Cancer Institute: HGFAC | ||
Assigned class in TissGDB* | C | |
Included tissue-specific gene expression resources | HPA,GTEx | |
Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Liver | |
Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | LIHC | |
Reference showing the relevant tissue of HGFAC | ||
Description by TissGene annotations |
* Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO term | PubMed ID |
Top |
TissGeneExp for HGFAC |
Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
- Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
LIHC | 5.54968146 | 10.61695146 | -5.06727 | 3.45E-10 | 4.12E-09 |
KICH | -1.49770854 | 0.55351546 | -2.051224 | 3.53E-10 | 2.50E-09 |
KIRP | 2.154835585 | 0.84955746 | 1.305278125 | 0.0118 | 0.02546256 |
Top |
TissGene-miRNA for HGFAC |
Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
Top |
TissGeneMut for HGFAC |
TissGeneSNV for HGFAC |
nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
- nsSNVs sorted by frequency. |
AAchange | Cancer type | # samples |
p.P654S | SKCM | 2 |
p.F231L | COAD | 2 |
p.Y294* | UCEC | 1 |
p.G434W | UCEC | 1 |
p.K399N | CESC | 1 |
p.A218S | COAD | 1 |
p.E524K | STAD | 1 |
p.W236X | LIHC | 1 |
p.G478D | STAD | 1 |
p.V351L | LUAD | 1 |
p.P14L | COAD | 1 |
p.C245* | LUAD | 1 |
p.K400N | CESC | 1 |
p.R650W | UCEC | 1 |
p.G167S | SKCM | 1 |
p.G254S | SKCM | 1 |
p.R646Q | UCEC | 1 |
p.P249H | KIRP | 1 |
p.V458I | GBM | 1 |
p.A191V | UCEC | 1 |
p.A51V | COAD | 1 |
p.W310C | SKCM | 1 |
p.P377S | SKCM | 1 |
p.T476P | UCS | 1 |
p.S92L | HNSC | 1 |
p.K131E | LUAD | 1 |
p.R396W | LIHC | 1 |
p.E480K | SKCM | 1 |
p.G214C | BRCA | 1 |
p.V225M | BRCA | 1 |
p.S62Y | LUAD | 1 |
p.E556K | SKCM | 1 |
p.P389S | SKCM | 1 |
p.F112L | STAD | 1 |
p.G214C | COAD | 1 |
p.G623R | CESC | 1 |
p.G296V | COAD | 1 |
p.G239D | KICH | 1 |
p.C175R | STAD | 1 |
p.E238K | SKCM | 1 |
p.R644Q | BRCA | 1 |
p.R117C | ACC | 1 |
p.E205* | CESC | 1 |
p.E76D | UCEC | 1 |
p.R117H | HNSC | 1 |
p.G614S | GBM | 1 |
p.V437F | LUAD | 1 |
p.G253E | STAD | 1 |
p.R633H | STAD | 1 |
p.P601A | STAD | 1 |
p.F112L | CESC | 1 |
p.R31W | BLCA | 1 |
p.R117H | STAD | 1 |
p.Y361X | KIRP | 1 |
p.G167S | HNSC | 1 |
p.G194D | PAAD | 1 |
p.E229Q | BLCA | 1 |
p.V473M | LIHC | 1 |
p.C521Y | BRCA | 1 |
p.D564N | STAD | 1 |
p.G39V | LUAD | 1 |
p.T193I | SKCM | 1 |
p.E480K | STAD | 1 |
p.A424P | LUAD | 1 |
p.W640* | SKCM | 1 |
p.A563T | PRAD | 1 |
p.G428V | THYM | 1 |
p.H185Q | UCEC | 1 |
p.R624W | BRCA | 1 |
p.R109K | UCEC | 1 |
Top |
TissGeneCNV for HGFAC |
Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
Top |
TissGeneFusions for HGFAC |
Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
Top |
TissGeneNet for HGFAC |
Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
Top |
TissGeneProg for HGFAC |
Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Top |
TissGeneClin for HGFAC |
TissGeneDrug for HGFAC |
Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
TissGeneDisease for HGFAC |
Disease information associated with TissGene (DisGeNet, 2016-06-01) |
Disease ID | Disease name | # pubmeds | Source |
umls:C2239176 | Liver carcinoma | 3 | BeFree,CTD_human |
umls:C0036572 | Seizures | 2 | BeFree |
umls:C0376358 | Malignant neoplasm of prostate | 2 | BeFree |
umls:C0600139 | Prostate carcinoma | 2 | BeFree |
umls:C0001418 | Adenocarcinoma | 1 | BeFree |
umls:C0003130 | Anoxia | 1 | LHGDN |
umls:C0005411 | Biliary Atresia | 1 | BeFree |
umls:C0007103 | Malignant neoplasm of endometrium | 1 | BeFree |
umls:C0007134 | Renal Cell Carcinoma | 1 | BeFree |
umls:C0007847 | Malignant tumor of cervix | 1 | BeFree |
umls:C0017636 | Glioblastoma | 1 | BeFree |
umls:C0020503 | Hyperparathyroidism, Secondary | 1 | GAD |
umls:C0025149 | Medulloblastoma | 1 | BeFree |
umls:C0025202 | melanoma | 1 | BeFree |
umls:C0026764 | Multiple Myeloma | 1 | LHGDN |
umls:C0027627 | Neoplasm Metastasis | 1 | BeFree |
umls:C0029925 | Ovarian Carcinoma | 1 | BeFree |
umls:C0030297 | Pancreatic Neoplasm | 1 | LHGDN |
umls:C0041341 | Tuberous Sclerosis | 1 | BeFree |
umls:C0079731 | B-Cell Lymphomas | 1 | LHGDN |
umls:C0235974 | Pancreatic carcinoma | 1 | BeFree |
umls:C0239946 | Fibrosis, Liver | 1 | BeFree |
umls:C0280631 | Leiomyosarcoma of uterus | 1 | BeFree |
umls:C0302592 | Cervix carcinoma | 1 | BeFree |
umls:C0346647 | Malignant neoplasm of pancreas | 1 | BeFree |
umls:C0476089 | Endometrial Carcinoma | 1 | BeFree |
umls:C0596263 | Carcinogenesis | 1 | BeFree |
umls:C0677886 | Epithelial ovarian cancer | 1 | BeFree |
umls:C1140680 | Malignant neoplasm of ovary | 1 | BeFree |
umls:C1561955 | Fibrinogen Adverse Event | 1 | GWASCAT |
umls:C1883486 | Uterine Corpus Cancer | 1 | BeFree |